Latest News - Cencora
Top Corporates Hub
Cencora
Cencora Remains A Buy At These Prices, As Healthcare Supply-Chain Needs Grow
06.10.2026 03:48
Despite some market underperformance, Cencora's specific business and macro fundamentals remain supportive. Read why COR stock is a Buy.
Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release
02.10.2026 12:00
CONSHOHOCKEN, Pa., October 02, 2026--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2026 on Wednesday, November 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 4, 2026.
Cardinal Health: I'm Still Buying After Checking The Numbers
30.09.2026 15:01
Cardinal Health remains a Buy, driven by robust FY2026 results, strong cash flow, and credible FY2027 guidance. Read more on CAH stock here.
Cencora Elects Robert E. Sanchez to Its Board of Directors
25.09.2026 12:00
CONSHOHOCKEN, Pa., September 25, 2026--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026.
Can CAH's MSO Expansion Unlock Growth in Specialty Care Delivery?
22.09.2026 13:32
CAH is expanding its MSO strategy across specialty care, with Solaris and broader services aimed at scaling physician networks.
Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference
21.09.2026 10:02
Cencora (NYSE:COR) executives highlighted the company’s specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while reaffirming the durability of its relationship with Walgreens. Chief Executive Offi
Cencora (COR) Lifts EPS Outlook And Buyback, Is The Stock Still Below Fair Value?
20.09.2026 14:08
Cencora (COR) just combined a stronger fiscal third quarter, a higher full year adjusted EPS outlook, and a US$1b buyback with plans to brief investors at two New York healthcare conferences. Despite the upbeat earnings message, Cencora’s share price has eased in the short term, with a 7 day share price return of down 3.98% and a 30 day share price return of down 2.91% from US$308.78. At the same time, a 90 day share price return of 13.82% and a 1 year total shareholder return of 7.28% sit...
Cencora (COR) Raised Guidance and Bought Back $1B. What’s the Catch?
19.09.2026 12:38
On August 5, Cencora (NYSE:COR) reported results for its fiscal third quarter, which closed on June 30, and the headline numbers looked clean. Revenue rose 5.1% to $84.8 billion, adjusted earnings per share climbed 12.0% to $4.48, and management raised its full-year adjusted EPS outlook to $17.75 to $17.95. The company also repurchased $1 billion […]
The Realities of Managing Enterprise AI
15.09.2026 14:29
A panel of CIOs from Indeed, New York Life and Cencora discuss the risks and advantages of enterprise AI, including operational efficiency, financial waste and the need to implement “control towers” for human oversight of consequential decisions.
Cencora, Inc. (COR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
15.09.2026 11:01
Cencora, Inc. (COR) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 8:30 AM EDTCompany ParticipantsRobert Mauch - President, CEO...
Coultreon Biopharma Appoints Nate Massari as Chief Business Officer
14.09.2026 13:00
Nate Massari’s business development and commercialization expertise in Immunology & Inflammation (I&I), particularly in ulcerative colitis and Crohn’s disease, will support the advancement of Coultreon's first-in-class SIK3 inhibitor COL-5671 Leuven, Belgium. September 14, 2026. Coultreon Biopharma, a clinical-stage biotechnology company developing best-in-class immunology therapies, today announced the appointment of Nate Massari as Chief Business Officer. Nate brings more than 25 years of expe
Cencora (NYSE:COR): A Quality Stock With Strong EBIT Growth and Cash Conversion
14.09.2026 08:11
Cencora (COR) scores well on EBIT growth, cash-backed profits and debt/FCF, but thin margins and high debt/equity warrant caution for quality investors.
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
11.09.2026 15:49
Amgen is profitable and paying a growing dividend, while Revolution Medicines is burning cash to fund what could be one of the most important cancer drug launches in years.
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
11.09.2026 15:29
One company is generating billions in revenue and raising its dividend. The other is burning cash in pursuit of a scientific breakthrough that could change how diseases are treated.
Cencora, Inc. (COR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
08.09.2026 12:25
Cencora, Inc. (COR) Wells Fargo 21st Annual Healthcare Conference September 8, 2026 9:30 AM EDTCompany ParticipantsRobert Mauch - President, CEO &...
RBC Capital Reiterates Sector Perform on Cencora, Maintains $330 Price Target
08.09.2026 10:37
RBC Capital analyst Ryan Halsted reiterates Cencora (NYSE:COR) with a Sector Perform and maintains $330 price target.
Artisan Sold Cencora (COR) as Earnings Momentum Slowed
03.09.2026 13:11
Artisan Partners, an investment management company, released its second-quarter 2026 investor commentary for the “Artisan Global Opportunities Strategy”. The letter can be downloaded here. Global equities rebounded sharply during the quarter, with the MSCI ACWI Index returning 15.3% as resilient economic growth, strong corporate earnings, and continued enthusiasm around artificial intelligence supported markets despite persistent inflation, […]
Cencora’s Accelerate Pharmacy Solutions Launches Cell and Gene Therapy Enablement to Help Health Systems Build and Scale Programs
02.09.2026 13:30
CONSHOHOCKEN, Pa., September 02, 2026--Cencora today launched a service to help health systems evaluate, build and scale cell and gene therapy (CGT) programs. Offered through Accelerate Pharmacy Solutions, Cell and Gene Therapy Enablement is designed to help health systems strengthen operational readiness and program execution to reduce barriers to care and expand patient access to advanced therapies.
RBC Capital Initiates Coverage On Cencora with Sector Perform Rating, Announces Price Target of $330
19.08.2026 09:46
RBC Capital analyst Ryan Halsted initiates coverage on Cencora (NYSE:COR) with a Sector Perform rating and announces Price Target of $330.